Synaptic Bio, First-Place IPC Winner at RESI Boston: Building a Next-Generation Checkpoint Therapy

Synaptic Bio, the First-Place winner of the Innovator’s Pitch Challenge at RESI Boston, is advancing a tetravalent bispecific antibody designed to improve both the efficacy and tolerability of cancer immunotherapy. In this interview, the team shares how SYB302 applies immune synapse biology to PD-1 therapy, its path toward the clinic, and the investor and partnering conversations sparked at RESI. 

Yotam Levin
CEO and Co-Founder at Synaptic Bio
Caitlin Dolegowski
Program Director, LSN

Caitlin Dolegowski (CD): Introduce Synaptic Bio and the unmet need you are addressing in cancer immunotherapy. 

Yotam Levin (YL): Synaptic Bio is a spinout from Dr. Adam Mor’s lab at Columbia University, building bispecific antibodies around the biology of the immune synapse, the interface where a T cell and a tumor cell engage. Our lead program, SYB302, pairs a next-generation PD-1 blocker with IL-25 neutralization in a single asset. Checkpoint inhibitors (ICIs) transformed oncology, but they leave a lot of patients behind. Roughly 800,000 people in the US are treated with ICIs each year, but an estimated 480,000 don’t respond. About half overall develop immune-related adverse events, an expected side effect of bolstering the immune system, and an estimated 140,000 patients have to stop therapy because of severe ones. So there are two problems: too few patients respond, and too many who do respond are forced off a drug that was working. We designed SYB302 to address both concerns.

CD: How does your tetravalent bispecific platform, including SYB302, leverage immune synapse biology to differentiate it from existing checkpoint therapies? 

YL: Today’s PD-1 antibodies mainly work by blocking PD-1 from binding its ligand. SYB302 adds a physical mechanism. Its PD-1 arms are long, and the molecule is larger than a standard antibody. That size pushes PD-1 out of the immune synapse so it can’t suppress the T cell. We have a cool movie on our website at www.synaptic-bio.com to show this. The tetravalent design adds a second mechanistic layer. IL-25 is a homodimer, so each IL-25 molecule can bridge two SYB302 antibodies. That clusters PD-1 on the T cell surface and drives its internalization and degradation. IL-25 is abundant in the tumor microenvironment, so the effect is strongest where we want it. IL-25 is also a driver of immune-related toxicity. Neutralizing this cytokine gives us a built-in safety brake. In preclinical models, including colon, melanoma, and bladder tumors, SYB302 showed stronger tumor control than anti-PD-1 with markedly less organ damage. A single antibody designed to improve both efficacy and tolerability – we have not seen any other antibody that does both.

CD: What are the most important scientific or development milestones over the next 12 to 18 months? 

YL: Our focus is moving SYB302 from a mature Development Candidate toward the clinic. The key milestones are:

  1. Stable cell line and process: completing cell line development and defining the manufacturing process, targeted around month 9 after funding.
  1. FDA engagement: a pre-IND meeting, targeted around month 12.
  1. GMP and toxicology: starting GMP manufacturing and GLP toxicology, leading to an IND submission at about month 24.

In parallel, we’ll expand our preclinical data in colorectal cancer and other indication-specific models, characterize IL-25 as a potential patient-selection biomarker, and advance the manuscript describing the SYB302 data. Colorectal cancer, particularly the MSS subtype that responds poorly to current checkpoint inhibitors, is our lead indication. CRC is a very prevalent disease with few treatment options. As supported by the biology of IL-25, this tumor shows that having high levels of IL-25 correlates highly with poor overall survival.

CD: What did being named First Place winner of the Innovator’s Pitch Challenge at RESI Boston mean to your team? 

YL: It was a meaningful validation, especially coming from an audience of investors and industry experts who evaluate hundreds of stories a year. Our science comes from a university lab and takes a different approach to PD-1 biology, so it’s rewarding to see that message resonate with people who understand the field. It also reinforces our conviction that the next generation of checkpoint therapy needs to deliver both better efficacy and better tolerability.

Preparing for the pitch was fun, because we had to distill a 30 to 60-minute story into a mere six minutes. This forced substantial simplification on one hand, but it also required us to ensure a sophisticated audience gets what they came for – understanding the essence of what we do. The most critical listener in the audience was, of course, Professor Mor – the fact that he liked the presentation was yet another award.

CD: What aspects of the RESI experience, including the pitch, judge feedback, or partnering conversations, were most valuable? 

YL:

  1. The pitch: We had to make multiple decisions on what to leave behind and not share. It’s like asking – of the 12 major value propositions of your assets, what are the one and a half that you really need to focus on?
  2. Judge feedback: The judges were very insightful, despite the brevity of the presentation and lack of detail. One asked about breakdown of budgets and its assumptions, identifying some assumptions we’ve taken without showing them. I was happy we could answer the questions quickly without to use backup slides for an answer.
  3. RESI Sessions: We really enjoyed the panels because they brought industry leaders and experienced investors. We could get a much better feel for what individual fund managers expect to see, how they differ from one another, how to overcome the overwhelming noise of hundreds of pitches and business plans, and whether or not there is a likely fit with certain parties. Meeting these investors in person instead of through email, Zoom, or networking apps made all the difference.

CD: Did RESI Boston lead to any meaningful investor, strategic partner, or scientific conversations that you expect to continue? 

YL: Yes. We had productive conversations with a few investors and potential strategic partners, and several are in the funnel. I can’t share specifics of course, but the interest has been in both SYB302 and the broader platform.

CD: What types of investors or strategic partners would be most valuable, and why should other early-stage companies consider the Innovator’s Pitch Challenge? 

YL: We’re looking for partners who understand the immuno-oncology landscape and can support a long development path. That includes biotech-focused venture investors for our seed financing, and strategic partners in oncology and immunology who see the value of a differentiated PD-1 backbone. For our lead asset, we prefer traditional seed funding; for our additional assets in Type2 inflammation we also foresee single-asset licensing, option-based co-development or a strategic investment. We think corporate VCs could be a natural fit, because they have deep scientific expertise but also an eye for market access. Our strongest asset is our science, data, and results – having experienced investors in our team would go a long way.

Apply to Pitch at RESI JPM 2027

Hot Investor Mandate: U.S.-Based Angel Investment Group Seeking Seed-Stage Medical Device and Diagnostics Opportunities ($100K–$250K)

A U.S.-based angel investment group invests in seed-stage life sciences and technology companies. The firm’s typical initial investment ranges from $100,000 to $250,000, structured as either secured convertible debt with interest and a discount upon conversion to preferred shares, or direct investments in preferred equity. Geographically, the firm focuses on opportunities in the United States, Canada, and Israel. 

Within life sciences, the investor is primarily interested in early-stage medical devices and diagnostics. The firm is flexible regarding technology types and therapeutic indications, provided the solutions address meaningful medical needs. The investor also considers therapeutics companies, with a preference for those that have reached the early clinical stage. The firm generally avoids investments in purely digital applications. 

The firm does not have specific company or management team requirements and can provide active advisory support to portfolio companies as needed. The investor prefers to co-invest alongside larger investment groups rather than lead financing rounds and seeks companies with a clear potential exit pathway within three to five years. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: North American Family-Owned Investment Firm Seeking Opportunities Across Healthcare Sectors

A Canada-based, family-owned investment firm with a background in manufacturing invests in both public and private companies across a variety of industries, including healthcare and biotechnology. For private investments, the firm’s typical check size ranges from $1 million to $5 million. The firm generally prefers participating in investment rounds rather than leading them and primarily focuses on opportunities in North America. 

The firm is industry-agnostic and open to opportunities across medtech, biotech, digital health, and healthtech. The investor prefers companies that are closer to commercialization rather than those in the preclinical or early clinical stages, where it can leverage its expertise in commercialization and revenue growth to support portfolio companies. 

The firm does not have specific company or management team requirements, although founding teams with successful track records are viewed favorably.

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: Europe Based Early-Stage Life Sciences VC Seeking Novel Therapeutics Opportunities with $3M–$5M Initial Investments

A Europe-based venture capital firm founded by entrepreneurs with extensive life sciences and biotechnology experience focuses exclusively on novel therapeutics. The firm invests at the earliest stages of development, from Seed through late preclinical programs, typically supporting assets through clinical proof of concept and seeking exits following meaningful clinical validation. The firm is currently investing from an existing fund primarily focused on Europe and is nearing the end of its deployment period. The investor plans to raise its next fund in the near term, with an anticipated stronger focus on U.S. opportunities. 

The firm typically makes initial equity investments ranging from $3 million to $5 million and may also consider convertible loan structures where appropriate. It has the capacity to invest approximately $15 million to $20 million per company over the life of an investment. The firm participates in both company creation and investment syndicates alongside other specialist biotech investors. 

The investor focuses exclusively on therapeutics and is indication- and modality-agnostic. It seeks novel drug candidates with strong scientific rationale, differentiated mechanisms of action, significant unmet medical needs, and high commercial potential. The firm’s primary considerations are the stage of development, scientific differentiation, and commercial opportunity rather than specific therapeutic areas or modalities. 

The firm sources opportunities through its global network of biotech founders, academic researchers, and entrepreneurial management teams. Following investment, it works closely with portfolio companies to execute R&D strategies, optimize capital allocation, and prepare for future financing rounds or strategic transactions. While historically focused on Europe, the firm takes a geographically opportunistic approach and evaluates opportunities based on scientific merit, valuation, and potential risk-adjusted returns. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

Hot Investor Mandate: US-based Corporate Venture Investor Backed by Japanese Manufacturer Seeking Early-Stage Opportunities in Life Sciences, Diagnostics, and Biotech Tools 

A U.S.-based corporate venture capital firm backed by a Japanese chemical manufacturer is seeking investment opportunities in emerging markets, including life sciences and healthcare. The firm invests from Seed stage onward, with a preference for Series A and B opportunities, while remaining open to later-stage investments on a case-by-case basis. Investment amounts range from several hundred thousand to several million dollars, with the flexibility to make follow-on investments. 

The firm considers opportunities globally and works closely with its regional investment teams in Japan and East Asia to evaluate cross-border investments. 

While the firm has a background in chemicals and materials, it does not require portfolio companies to be materials-focused. Areas of interest include diagnostic platforms, AI and AI-enabled drug discovery, biotech tools, and other physical technologies, particularly those incorporating consumables or offering recurring consumables revenue opportunities. The firm is disease-agnostic and prefers companies that have demonstrated proof of concept or other evidence of technical feasibility and/or market potential. 

If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com. 

The Missing Piece in Preparing Life Science Companies for Investors

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

One of the most pervasive problems we see across life science entrepreneurial programs is that Entrepreneurs-in-Residence (EIRs) help companies develop executive summaries and pitch decks that emphasize the science and market opportunity. This approach repeats across incubators, accelerators, universities, and entrepreneurial training programs worldwide.

The problem is that the two sides of the table are speaking different languages. The sell side presents science and market potential, while investors and licensing partners evaluate the seven-layer risk stack: market, technical, regulatory, execution, economic, financing, and exit risk. They want to understand which risks have been retired, which remain, and what evidence supports the company’s ability to overcome them.

This is precisely where LSN spends its time preparing companies for global roadshows and RESI partnering events.

We begin with the LSN assessment, which identifies where the company sits within the risk stack, what has been accomplished, and what remains to be de-risked. We then reconstitute the executive summary and pitch deck to speak the language of risk, supported by evidence rather than simply promoting the science and market opportunity.

We also develop a milestone-driven Gantt chart that shows the development milestones already completed and the value created, the one, two, or three critical milestones ahead for the remainder of the current year, and the subsequent development and de-risking milestones planned for years two and three.

The capital ask becomes the financial expression of the de-risking plan. By calculating the cost of the current and future milestones, the company can explain precisely how much capital it needs, what that capital will accomplish, which risks will be retired, and how achieving those milestones is expected to increase the asset’s value.

This is the fundamental distinction between a conventional pitch deck and a de-risked deck. One emphasizes the promise of the science and the size of the market. The other demonstrates a credible, milestone-driven, financed pathway to making that science investable.

That is the missing commercialization discipline LSN brings to the table, and it is what investors and licensing partners are looking for.

Register for RESI JPM 2027

RESI JPM 2027 Investor Panel Lineup Announced 

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation is pleased to announce the finalized investor panel lineup for RESI JPM 2027, taking place January 11 and 12 at the San Francisco Marriott Marquis during J.P. Morgan Healthcare Week.

The two day program features 14 investor sessions across therapeutics, medtech, diagnostics, digital health, platform technologies, strategic partnerships, and alternative sources of capital.

Monday, January 11

9:00 AM | Follow the Money [2027 Outlook & Trends]

Where Life Science & Healthcare Investors See Opportunity in 2027

Every year at JPM, one question sets the tone for the week: where is the capital going? Investors from across therapeutics, medtech, diagnostics, digital health, and tools take the stage to share what they are seeing in fundraising, valuations, and exit windows. They will discuss which sectors are attracting conviction, which are being left behind, and how their own priorities have shifted since last year. Whether you are raising, investing, or building, this is the read on the market you need before the deals begin.

10:00 AM | What Is Fundable Now: Therapeutics [Early Stage Therapeutics]

What Earns a Term Sheet from Early Stage Biotech Investors

Early stage therapeutics investors must weigh scientific promise against the risks of translating it into a viable treatment. Seed through Series A investors get candid about what earns their conviction: differentiated biology, convincing translational evidence, and a credible clinical development strategy. The discussion explores how investors assess target validation, competitive positioning, safety, and the experiments needed to reduce key development risks. Expect frank talk about what makes them lean in, what makes them pass, and how founders can make a compelling scientific and investment case for a therapeutic program.

11:00 AM | Backing the Next Medical Breakthrough [Medical Devices]

How Investors Evaluate Early Stage Device Innovation

Medical device companies face distinct investment hurdles, from proving technical feasibility to establishing a path to clinical adoption. This panel brings together medtech investors to discuss how they evaluate early stage opportunities across surgical technologies, robotics, monitoring, wearables, and home care. The conversation examines clinical need, regulatory strategy, reimbursement, usability, and the evidence required to support adoption. Hear what makes a device differentiated, how investors assess development and commercial risk, and which milestones strengthen the case for investment.

1:00 PM | Strategics at the Table [Strategics]

How Corporate Partners Decide When to Invest, Partner & Acquire

Strategic partners are shaping which technologies reach patients, and they are increasingly involved long before a company is ready to sell. Business development leaders from pharma and medtech join corporate venture investors to explain when they engage, what they need to see, and how they think about partnering, investing, and acquiring. Learn how to get on a strategic partner’s radar, what makes a startup stand out in a crowded pipeline, and how to build a relationship that lasts beyond a single deal.

2:00 PM | The First Believers [First Check Investors]

How the Earliest Backers Turn Life Science Ideas into Fundable Companies

Every great company has someone who said yes first. This panel gathers the earliest backers in life sciences: angels, seed funds, venture studios, foundations, and accelerators. They explain how they evaluate opportunities before substantial scientific or commercial validation, what they look for in a founding team, and what gives them the conviction to write the first check. The conversation covers company formation, initial experiments, and how early capital and hands on support help founders establish a credible development path. For founders at the very start, it is a candid map of the road from initial concept to the first funded development milestones.

3:00 PM | The Brain Trust [CNS / Neuro]

Investing Across Neuroscience & Psychiatry

Few areas of medicine combine such enormous unmet need with such complex investment challenges. This panel brings together investors in therapeutics, neuromodulation devices, digital biomarkers, and diagnostics to discuss what draws capital into neuroscience and psychiatry. Together they explore how advances in biology, technology, and clinical trial design can reopen areas once considered too difficult, and how founders across modalities can position themselves to attract investment.

4:00 PM | Patient Capital [Family Offices]

How Family Offices Are Investing Directly in Life Sciences

Family offices offer a distinct route to life science capital through direct investing, syndication with peers, and investment structures that can support longer time horizons. This session explores what draws private capital to highly technical opportunities, how family offices diligence science and technology, and what founders should know before approaching them. Panelists discuss how they structure investments, work with specialist co-investors, and assess follow-on needs. It is a practical look at how to earn the confidence of this diverse investor community.

Tuesday, January 12

9:00 AM | Investing in Longer, Healthier Lives [Longevity]

The Science and Technologies Addressing Age Related Disease

Helping people live longer, healthier lives requires addressing the diseases and functional challenges that come with aging. This panel brings together therapeutics, medtech, diagnostics, and digital health investors to explore opportunities in cardiometabolic disease, musculoskeletal health, physical function, and maintaining independence. The discussion examines how investors evaluate treatments for specific age related conditions alongside technologies that address underlying aging biology, detect risk earlier, or help people remain active. Hear what constitutes meaningful clinical evidence, how companies define a viable path to market, and what makes an opportunity compelling for early stage investment.

10:00 AM | Digital Health After the Hype [Digital Health]

What Investors Want to See in Evidence, Adoption & Economics

The digital health market has been through a reset. Investors discuss what they are backing now: clinical grade AI, new models of care delivery, and businesses with evidence, engagement, and economics that hold up to scrutiny. Hear where value is being created, what has changed in how these companies are evaluated, and what separates durable businesses from those that struggle to convert adoption into sustainable growth.

11:00 AM | Enabling the Next Generation of Medicine [Platform Technologies]

Investing in Discovery Platforms, Delivery Technologies & Research Tools

Some of the most valuable companies in life sciences make new medicines possible. This panel brings together investors backing AI enabled discovery platforms, delivery technologies, synthetic biology, and the research tools that accelerate development. The conversation centers on how to separate a durable platform from a clever technology, how investors evaluate platform companies alongside tools and infrastructure businesses, and how business models differ from those of asset driven companies. Hear what makes these technologies investable and where founders can build lasting value.

1:00 PM | Capital Across Borders [Cross Border Investors]

How International Investors Evaluate and Finance Life Science Companies

Cross border investment can expand a company’s funding options, but attracting international capital requires understanding how investors evaluate opportunities beyond their home markets. This panel brings together investors from different regions to discuss geographic mandates, due diligence, syndication, and the local presence or development plans they expect from companies abroad. Hear what makes a company attractive to overseas investors, how investors work with local co-investors, and how founders can build relationships that lead to cross border financing.

2:00 PM | Runway Without the Round [Beyond Venture Capital]

Financing the Next Milestone Beyond Conventional Venture Equity

A conventional venture round is not the only way to fund a company. This panel explores non dilutive grants, foundation funding, venture debt, royalty financing, strategic agreements, and government backed programs. Capital providers explain who qualifies, what stage or evidence their funding requires, how long the process takes, and what obligations or tradeoffs founders should understand. The discussion examines which sources are suitable for early stage companies and how they can complement equity financing. Hear how to match funding to a development milestone and extend runway without relying solely on another conventional venture round.

3:00 PM | From Seed to Series A

Building the Evidence and Investor Confidence for the Next Round

Securing seed funding is only the beginning. This panel brings together seed investors and Series A investors to explore how life science companies turn initial funding into a financeable next round. The discussion covers setting achievable milestones, demonstrating progress against the original investment thesis, identifying a lead investor, and building a syndicate. Across therapeutics, medtech, and digital health, panelists discuss how founders should align development plans, capital needs, and fundraising timelines. Hear how existing investors assess follow-on support, what new investors need to see, and how to address gaps that can leave promising companies between rounds.

4:00 PM | The Investor Reverse Pitch

Meet the Investors and Discover What They Want to Fund

To close the conference, the roles flip. Investors from across therapeutics, medtech, diagnostics, digital health, and tools take the stage to pitch their mandates: what they invest in, at which stage, with what check size, and what gets their attention. Investors deliver short presentations, followed by audience Q&A. Founders leave with a clear list of who to follow up with and how to approach them. It is a practical, high energy finish to two days of conversations.

Speaker Submissions

Life Science Nation is currently seeking qualified investors, corporate business development leaders, family office representatives, and other capital providers for speaker consideration. Submit a speaker application.

Submit a speaker application